Video

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

Biology is complicated. Our scientists work with large amounts of scientific data to better understand the relationship between biological entities.

Many of these pieces form a coherent picture about one segment of the biology in question, but often, scientists are presented with conflicting evidence. There are many gaps in the understanding of biology and many blanks remain to be filled. Understanding and filling these gaps is incredibly important for scientists to be able to select the right targets.  

At Benevolent we use various computational technologies and a range of standard and non-standard design patterns to help drug discoverers explore and select the best targets for validation. The role of our machine learning researchers, engineers and designers is to build this technology that helps our scientists break though this vastness of biological information to develop medicines for the patients that need them most.  

Marek, Lead Product Designer, gives a talk at World Usability Day Silesia 2019 in which explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.

More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022